null - FindTrial

N/A - ARCADE

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2015-001065-76-FR

Enrollment

169

Registered

2015-09-08

Start date

2015-09-28

Completion date

Unknown

Last updated

2020-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 18.0 Level: PT Classification code 10014316 Term: Ehlers-Danlos syndrome System Organ Class: 10010331 - Congenital, familial and genetic disorders

Interventions

Trade Name: IRBESARTAN Product Name: IRBESARTAN Pharmaceutical Form: Coated tablet INN or Proposed INN: irbesartan Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 169 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

France

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026